Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-10-12
2008-12-02
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S311000
Reexamination Certificate
active
07459447
ABSTRACT:
Provided is a method for treating hyperlipidemia or hypercholesterolemia, which comprises administering effective doses of ezetimibe and pitavastatin or a salt or lactone derivative thereof.
REFERENCES:
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5102888 (1992-04-01), Fujikawa et al.
patent: 5185328 (1993-02-01), Fukikawa et al.
patent: 5661145 (1997-08-01), Davis
patent: 5854259 (1998-12-01), Fujikawa et al.
patent: 5856336 (1999-01-01), Fujikawa et al.
patent: 5872130 (1999-02-01), Fujikawa et al.
patent: 6465477 (2002-10-01), Muramatsu et al.
patent: 6777552 (2004-08-01), Niddam-Hildesheim et al.
patent: 2004/0126423 (2004-07-01), Moore et al.
patent: 2004/0254120 (2004-12-01), Fogelman et al.
patent: 8-505141 (1996-06-01), None
patent: WO 95/08532 (1995-03-01), None
Harry R. Davis Jr. et al., “The Synergistic Hypocholesterolemic Activity of the Potent Cholesterol Absorption Inhibitor, Ezetimibe. In Combination With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Dogs”, Metabolism, vol. 50, No. 10, Oct. 2001, pp. 1234-1241.
Aoki Taro
Maejima Takashi
Yamazaki Hiroyuki
Henley, III Raymond J
Kowa Co. Ltd.
Nissan Chemical Industries Ltd.
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Method for treating hyperlipidemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating hyperlipidemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating hyperlipidemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4040560